BMS-986020, a Specific LPA₁ Antagonist, Provides Neuroprotection against Ischemic Stroke in Mice

• Hoofdauteurs: Bhakta Prasad Gaire (Auteur), Arjun Sapkota (Auteur), Ji Woong Choi (Auteur)
• Formaat: Boek
• Gepubliceerd in: MDPI AG, 2020-11-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.
• Notes: 10.3390/antiox9111097; 2076-3921
• Keywords: BMS-986020; transient middle cerebral artery occlusion (tMCAO); neuroprotective effects; long-term neuroprotection; neurogenesis; angiogenesis; Therapeutics. Pharmacology; RM1-950
• Source: Antioxidants, Vol 9, Iss 11, p 1097 (2020)

Stroke is a leading cause of death. Stroke survivors often suffer from long-term functional disability. This study demonstrated neuroprotective effects of BMS-986020 (BMS), a selective lysophosphatidic acid receptor 1 (LPA₁) antagonist under clinical trials for lung fibrosis and psoriasis, against both acute and sub-acute injuries after ischemic stroke by employing a mouse model with transient middle cerebral artery occlusion (tMCAO). BMS administration immediately after reperfusion significantly attenuated acute brain injuries including brain infarction, neurological deficits, and cell apoptosis at day 1 after tMCAO. Neuroprotective effects of BMS were preserved even when administered at 3 h after reperfusion. Neuroprotection by BMS against acute injuries was associated with attenuation of microglial activation and lipid peroxidation in post-ischemic brains. Notably, repeated BMS administration daily for 14 days after tMCAO exerted long-term neuroprotection in tMCAO-challenged mice, as evidenced by significantly attenuated neurological deficits and improved survival rate. It also attenuated brain tissue loss and cell apoptosis in post-ischemic brains. Mechanistically, it significantly enhanced neurogenesis and angiogenesis in injured brains. A single administration of BMS provided similar long-term neuroprotection except survival rate. Collectively, BMS provided neuroprotection against both acute and sub-acute injuries of ischemic stroke, indicating that BMS might be an appealing therapeutic agent to treat ischemic stroke.